UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): ~~August~~July 1521, ~~2017~~2025

~~eBullion,~~SKY ~~Inc.~~CONSTANT ~~(Exact~~CENTURY ~~name of registrant as specified in its charter)~~INC.

~~Delaware~~(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation)

Delaware

000-54956

46-2323674

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

~~000~~Room 1805-~~55523~~06, Tower 6, 33 Canton Road

~~(Commission~~Tsim ~~File~~Sha ~~Number)~~Tsui, Hong Kong00000

~~46-2323674~~(Address of principal executive offices & zip code)

(~~IRS Employer Identification No.~~+86) 18217702866

~~Room~~(Registrants’ ~~1805-06,~~telephone ~~Tower 6~~number)

33Check ~~Canton~~the ~~Road,~~appropriate ~~Tsim~~box ~~Sha~~below ~~Tsui~~if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

~~Hong~~☐ ~~Kong~~Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~(Address~~Securities ofregistered ~~principal~~pursuant ~~executive~~to ~~offices)~~Section 12(~~Zip Code~~b) of the Act:

~~+853~~Title ~~3187-4300~~of each class Trading Symbol(s) Name on each exchange on which registered N/A N/A N/A

~~Registrant’s~~Indicate ~~telephone~~by ~~number,~~check ~~including~~mark ~~area~~whether ~~code~~the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~______________________________________________~~Emerging Growth Company ☒

~~(Former~~If ~~name~~an oremerging ~~former~~growth ~~address~~company, indicate by check mark if ~~changed~~the ~~since~~registrant ~~last~~has ~~report.~~elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Check~~Item ~~the appropriate box below if the Form~~ 8-K.01 ~~filing~~Other ~~is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A~~Events.~~2. below):~~

oSky ~~Written~~Constant ~~communications~~Century ~~pursuant~~Inc. (the “Company”) is pleased to ~~Rule~~announce ~~425~~that ~~under~~it ~~the~~has ~~Securities~~entered ~~Act~~into ~~(17~~active ~~CFR~~and ~~230~~constructive preliminary discussions with Zhejiang Yiqikang Health Industry Co.~~425~~, Ltd. (“Yiqikang”), a AAA-rated enterprise in China, regarding a potential strategic combination between the two companies, including but not limited to a possible merger or acquisition. Both parties share a common vision and mutual interest in exploring deeper integration to jointly build a leading platform in the global health and wellness sector. These ongoing discussions reflect a shared recognition of the complementary strengths of both organizations and the significant potential benefits that may arise from a closer strategic relationship. Through potential integration of resources and capabilities, the parties believe there is meaningful opportunity to create long-term value and accelerate business growth.

oYiqikang ~~Soliciting~~is ~~material~~a ~~pursuant~~well-established enterprise in China’s health industry, dedicated to ~~Rule~~providing ~~14a~~scientific, systematic, and personalized health management solutions for chronic disease and sub-12health ~~under~~populations. ~~the~~Led ~~Exchange~~by ~~Act~~Chairwoman ~~(17~~Ms. ~~CFR~~Sun ~~240~~Limin, President Mr.~~14a~~ Zhu Lingen, and General Manager Ms. Zhu Yunqin, Yiqikang operates a comprehensive ecosystem covering assessment, intervention, tracking, and optimization, alongside testing, research, services, and care. Yiqikang has earned multiple AAA-~~12)~~rated certifications for its business credibility and service quality and maintains close cooperation with Beijing Huaxia Integrative Medicine Research Institute. The company actively integrates multiple patented technologies into its product development and service innovation, including selenium-rich sturgeon bone peptides, probiotic strains for functional health, and microencapsulated nattokinase. These innovations support Yiqikang’s long-term strategies in AI-driven health diagnostics, chronic disease research, and expansion of a nationwide health service network.

oBoth ~~Pre-commencement~~parties ~~communications~~are ~~pursuant~~exploring opportunities to ~~Rule~~collaborate ~~14d-2(b)~~in ~~under~~health management technologies, service network expansion, and resource integration. While the ~~Exchange~~discussions ~~Act~~are ~~(17~~positive ~~CFR~~and ~~240~~progressing, they remain at an exploratory stage.~~14d-2(b))~~ No binding agreement has been signed, and there can be no assurance that any transaction will be completed. Both parties recognize the significant potential benefits of a strategic combination and share a willingness to continue deepening discussions towards this direction.

oThe ~~Pre-commencement~~Company’s ~~communications~~corporate ~~pursuant~~structure toremains ~~Rule~~unchanged. ~~13e-4(c)~~The ~~under~~Company ~~the~~will ~~Exchange~~provide ~~Act~~timely ~~(17~~updates ~~CFR~~in ~~240~~accordance with applicable SEC disclosure requirements if there are any material developments.~~13e-4(c))~~

~~Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~1

~~On August 14, 2017, BRK, Inc., a Nevada corporation (the “Company”), announced that Chui Chui Li had resigned as a Chief Financial Officer, Secretary, Treasurer and director of the Company.~~SIGNATURES

~~Kee~~Pursuant ~~Yuen~~to ~~Choi,~~ the ~~Company’s~~requirements ~~current~~of ~~Chief~~the ~~Executive~~Securities ~~Officer~~Exchange ~~and~~Act aof ~~director~~1934, the registrant has ~~been~~duly ~~appointed~~caused ~~Chief~~this ~~Financial~~report ~~Officer,~~to ~~Secretary,~~be ~~and~~signed ~~Treasurer~~on ofits behalf by the ~~Company~~undersigned, thereunto duly authorized.

There are no family relationships between Mr. Choi and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company within the meaning of Item 401(d) of Regulation S-K under the U.S. Securities Act of 1933 (“Regulation S-K”). Since the beginning of the Company’s last fiscal year, the Company has not engaged in any transaction in which Mr. Tan had a direct or indirect material interest within the meaning of Item 404(a) of Regulation S-K.

	SKY CONSTANT CENTURY INC.
	(Name of Registrant)

Date: July 21, 2025	By:	*/s/ Zhiyang Zhang*
	Name:	Zhiyang Zhang
	Title:	Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EBULLION, INC.
Date: August 15, 2017	By:	/s/ Kee Yuen Choi
	Name:	Kee Yuen Choi
	Title:	President and Chief Executive Officer

Filing Compare · Sky Constant Century Inc.